Metrics as of 10/16/2026, 08:37 AM (Berlin time), refresh in progress.
Lantern Pharma Stock
Lantern Pharma Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Panna Sharma
- Employees
- 16
- Market cap
- $9 M
- IPO
- 11/06/2020
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials,…
Lantern Pharma stock: price history
1D
-0.9%
1W
-19.7%
1M
-60.8%
6M
-73.7%
YTD
-78.0%
1Y
-84.9%
2Y
-81.2%
5Y
-93.3%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~66% stronger price swings than usual
Ask the agents about Lantern Pharma
Analyst assessment of Lantern Pharma
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 10/08/2023
Lantern Pharma stock metrics
P/E
-0.41
P/B
-2.57
EV/EBITDA
-0.1
RETURN ON EQUITY
219.8%
NET MARGIN
0.0%
DEBT/EQUITY
-0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.2%
FLOAT SHARES
9,594,424
AVG. DAILY VOLUME (30D)
277,276
Insider transactions (SEC)
KEYSER D JEFFREY
Schalop Lee Troy
Institutional holders
Comparable stocks
Frequently asked questions about Lantern Pharma stock
What does Lantern Pharma do?
Lantern Pharma Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Panna Sharma, the company employs around 16 people.
The IPO was on 11/06/2020; the stock trades on NASDAQ under the ticker LTRN.
What do analysts say about Lantern Pharma stock?
3 analysts rate the stock, the consensus is Buy (as of 10/08/2023).
This is an external assessment, not a statement by Market Jury.
When does Lantern Pharma report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 66% stronger than usual.
Does Lantern Pharma pay a dividend?
No, Lantern Pharma currently does not pay a dividend.
Which stocks are comparable to Lantern Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lantern Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lantern Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.